Laurus Labs is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $22.0B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Laurus Labs's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | Approved May 2024 | $7.7B |
| Biktarvy | Gilead | Generic | 2036 | Settled Oct 2025 | $14.3B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Laurus Labs's share of it.